A recent study published in The Lancet Regional Health - Southeast Asia journal indicates that a higher dose of the COVID-19 drug, dexamethasone, may have varying effects for patients in India compared to those in Europe. The research focused on assessing the efficacy of a robust dose of dexamethasone in treating COVID-19 patients, considering factors such as patient differences and health systems.

Related Keywords

Mumbai , Maharashtra , India , New Delhi , Delhi , Australia , Chennai , Tamil Nadu , Copenhagen , Køavn , Denmark , , Homi Bhabha National Institute , Copenhagen University Hospital , University Of New South Wales , George Institute For Global Health , Lancet Regional Health , Apollo Hospitals , George Institute , Global Health , New South Wales , Covid , Lancet , Study , Europe , Pandemic , Covid 19 , Indian Patients , Hospital ,